Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $48.7200 (0.35%) ($48.7200 - $48.7200) on Thu. Apr. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.57% (three month average) | RSI | 47 | Latest Price | $48.7200(0.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(64%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.785% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-18%) UNG(-3%) IGOV(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.785% (StdDev 3.57%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $46.31(5.2%) | 10 Day Moving Average | $47.08(3.48%) | 20 Day Moving Average | $46.91(3.86%) | To recent high | -10% | To recent low | 16.9% | Market Cap | $6.17b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |